Search Results - "Festini, Moreno"

Loss-of-function mutations in the histone methyltransferase EZH2 promote chemotherapy resistance in AML by Kempf, Julia M., Weser, Sabrina, Bartoschek, Michael D., Metzeler, Klaus H., Vick, Binje, Herold, Tobias, Völse, Kerstin, Mattes, Raphael, Scholz, Manuela, Wange, Lucas E., Festini, Moreno, Ugur, Enes, Roas, Maike, Weigert, Oliver, Bultmann, Sebastian, Leonhardt, Heinrich, Schotta, Gunnar, Hiddemann, Wolfgang, Jeremias, Irmela, Spiekermann, Karsten

“…Chemotherapy resistance is the main impediment in the treatment of acute myeloid leukaemia (AML). Despite rapid advances, the various mechanisms inducing…”
Get full text

Targeting FLT3 with a new-generation antibody-drug conjugate in combination with kinase inhibitors for treatment of AML by Roas, Maike, Vick, Binje, Kasper, Marc-André, Able, Marina, Polzer, Harald, Gerlach, Marcus, Kremmer, Elisabeth, Hecker, Judith S., Schmitt, Saskia, Stengl, Andreas, Waller, Verena, Hohmann, Natascha, Festini, Moreno, Ludwig, Alexander, Rohrbacher, Lisa, Herold, Tobias, Subklewe, Marion, Götze, Katharina S., Hackenberger, Christian P. R., Schumacher, Dominik, Helma-Smets, Jonas, Jeremias, Irmela, Leonhardt, Heinrich, Spiekermann, Karsten

“…•FLT3 is a promising target for ADCs in AML therapy.•Combination with midostaurin enhances the effectivity of FLT3-ADC in FLT3-ITD–mutated AML. [Display…”
Get full text